| Objective: To explore the effects of Bufei Xiaoji Yin combined with bevacizumab plus chemotherapy on the short-term efficacy,quality of life score,safety,tumor marker levels and other related clinical efficacy indexes in the treatment of advanced non-squamous non-small cell lung cancer(NSCLC)with Qi and Yin deficiency.Methods: Data of 87 patients with advanced non-squamous and non-small cell lung cancer admitted to our hospital from January 2020 to April 2022 were selected for retrospective study,and the patients were divided into control group(43 patients)and treatment group(44 patients)according to whether they took traditional Chinese medicine.Bevacizumab plus chemotherapy was routinely administered in both groups,and the treatment group was additionally treated with Bufei Xiaoji Yin,a traditional Chinese medicine,on the basis of the control group.The therapeutic effect of both groups was evaluated every 2 cycles,and at least 2 cycles were completed,and the short-term efficacy was compared.progression-free survival(PFS),tumor markers(CEA,CA125),VEGF,Karnofsky score and adverse reactions were different.Results:(1)Baseline data: The treatment group and the control group were compared in terms of sex,age,TNM stage,Beva combined with chemotherapy regimen,distant metastasis,smoking history,and blood pressure.The results showed that the differences between the two groups were not statistically significant(P>0.05),and the general data of the two groups were comparable.(2)Hierarchical distribution of progression-free survival by single factor:Log-rank analysis showed that there was a statistical difference in TNM stage(P<0.05).There were no significant differences in gender,bevacizumab plus chemotherapy regimen,distant metastasis and smoking history(P>0.05).(3)PFS: The median PFS of 87 patients was 15.22 months,the median PFS of the treatment group was 15.67 months and the median PFS of the control group was 14.67 months.The curative effect of the treatment group was better than that of the control group.P<0.05,with statistical difference.(4)Short-term efficacy: the total effective rate of the treatment group was 90.9%,and the total effective rate of the control group was 81.4%.The total effective rate of the treatment group was higher than that of the control group,but P>0.05,and there was no statistical significance in comparison between groups.The ORR of the control group was 34.8%,and that of the treatment group was 40.1%.The effective rate of the treatment group was higher than that of the control group,but P>0.05,without statistical significance.(5)TCM symptom score: After treatment,the TCM symptom score level of the two groups was significantly decreased(P<0.05),and the difference was statistically significant;After treatment,the TCM symptom integral statistical level of cough and phlegm,dry mouth and throat,dry stool,appetite loss,chest tightness and chest pain,upset and insomnia,fatigue in the treatment group was better than that in the control group,P<0.05,and the difference was statistically significant.(6)Tumor markers: After treatment,carcinoembryonic antigen(CEA),serum glucose antigen(CA125)and serum VEGF content in 2 groups were decreased,and the total effective rate of the treatment group was significantly higher than that of the control group,with statistical significance(P<0.05).(7)KPS score: After treatment,the total effective rate of KPS score in the treatment group was 45.4% higher than that in the control group 25.6%,the stability rate in the treatment group was 95.4% higher than that in the control group 88.3%,and the difference was statistically significant(P<0.05).(8)Adverse reactions: The incidence of adverse reactions in the control group was higher than that in the treatment group,which occurred during treatment and after drug withdrawal.The incidence of hypertension,bone marrow suppression and adverse reactions on the hands and feet of the two groups were compared,and the difference was statistically significant(P <0.05).There was no statistical significance in albuminuria,bleeding and digestive tract reaction(P>0.05).Conclusion(s): The combination of Bufei Xiaoji Yin and bevacizumab plus chemotherapy in the treatment of advanced non-squamous and non-small cell lung cancer with Qi and Yin deficiency has significant clinical efficacy,which can reduce the adverse reactions caused by vascular targeting drugs and chemotherapy drugs,improve patients’ quality of life,and improve clinical discomfort symptoms. |
PDF Full Text Request